Fearing cross contamination might have occurred during manufacturing, Scynexis Inc. is recalling Brexafemme (ibrexafungerp tablets) from the market and putting a temporary hold on the drug’s clinical trials until it knows more details.
Westvac Biopharma Co. Ltd. has described keto amide derivatives acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Via Nova Therapeutics Inc. has received clearance of its IND application from the FDA for its influenza A nucleoprotein inhibitor, VNT-101. The novel investigational small molecule is directed against a novel target, the influenza A nucleoprotein, and is being developed for treatment of seasonal influenza A infection.
Researchers at Ningbo Combireg Pharmaceutical Technology Co. Ltd. and Versitech Ltd. have described benzothiazole compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have disclosed zwitterionic compounds reported to be useful for the treatment of bacterial infections.
Transimmune AG has been awarded a $5 million investment from the Bill & Melinda Gates Strategic Investment Fund that will be used to leverage Transimmune’s physiologically induced dendritic cells (phDCs) to enhance the potency of mRNA vaccines in infectious diseases. The initial focus will be on a therapeutic vaccine for people with HIV.
Spybiotech Ltd. has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate SPYVLP-01, a vaccine targeting human cytomegalovirus (CMV) using its hepatitis B virus-like-particle platform technology.
Phaxiam Therapeutics SA has initiated a new preclinical development program targeting Klebsiella pneumoniae, which is responsible for severe infections and notable for its high resistance to antibiotics.
RSS
